Economic evaluation of long-term management strategies for erosive oesophagitis (Q33867824)

29 July 2017

title

Economic evaluation of long-term management strategies for erosive oesophagitis (English)

1 reference

29 July 2017

Goeree R

1

1 reference

29 July 2017

O'Brien B

2

1 reference

29 July 2017

Hunt R

3

1 reference

29 July 2017

Blackhouse G

4

1 reference

29 July 2017

Willan A

5

1 reference

29 July 2017

Watson J

6

1 reference

29 July 2017

publication date

1 December 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

16

1 reference

29 July 2017

issue

6

1 reference

29 July 2017

page(s)

679-697

1 reference

A double‐blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis : a multicentre trial

29 July 2017

cites work

1 reference

12 December 2020

Incorporating variability in estimates of heterogeneity in the random effects model in meta-analysis

1 reference

12 December 2020

Comparison of ranitidine, domperidone maleate and ranitidine domperidone maleate in the short-term treatment of reflux oesophagitis

1 reference

12 December 2020

Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.

1 reference

12 December 2020

Cisapride and cimetidine in the treatment of erosive esophagitis

1 reference

12 December 2020

Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis

1 reference

12 December 2020

Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study

1 reference

12 December 2020

Short and long-term effect of two different dosages of ranitidine in the therapy of reflux oesophagitis

1 reference

12 December 2020

Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis

1 reference

12 December 2020

A comparison of five maintenance therapies for reflux esophagitis

1 reference

12 December 2020

Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis

1 reference

12 December 2020

Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Famotidine Erosive Esophagitis Study Group

1 reference

12 December 2020

Combination of ranitidine and cisapride in the treatment of reflux oesophagitis.

1 reference

12 December 2020

Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations

1 reference

12 December 2020

Combined therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind controlled trial

1 reference

12 December 2020

Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial

1 reference

12 December 2020

Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine

1 reference

12 December 2020

Sucralfate versus cimetidine in reflux oesophagitis. A double-blind clinical study

1 reference

12 December 2020

Sucralfate versus cimetidine in reflux esophagitis. A single-blind multicenter study.

1 reference

12 December 2020

Prevention of relapse in reflux esophagitis: a placebo controlled study of ranitidine 150 mg bid and 300 mg bid

1 reference

12 December 2020

Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy. Lansoprazole, a new proton pump inhibitor

1 reference

12 December 2020

Meta-analysis in clinical trials

1 reference

12 December 2020

Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety

1 reference

12 December 2020

Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group

1 reference

12 December 2020

Ranitidine for erosive oesophagitis: a double-blind, placebo-controlled study. Glaxo Erosive Esophagitis Study Group

1 reference

12 December 2020

Ranitidine, 150 mg three times a day, in the treatment of reflux oesophagitis. A placebo-controlled, double-blind study

1 reference

12 December 2020

Effect of cisapride on relapse of esophagitis. A multinational, placebo-controlled trial in patients healed with an antisecretory drug. The Italian Eurocis Trialists

1 reference

12 December 2020

Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H /K( )-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group

1 reference

12 December 2020

Healing of grade-II and III oesophagitis through motility stimulation with cisapride

1 reference

12 December 2020

Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group

1 reference

12 December 2020

Gastroesophageal reflux. Pathogenesis, diagnosis, and therapy

1 reference

12 December 2020

Healing and relapse of severe peptic esophagitis after treatment with omeprazole

1 reference

12 December 2020

Ranitidine vs metoclopramide in the medical treatment of reflux esophagitis

1 reference

12 December 2020

Ranitidine 300 mg twice daily and 150 mg four-times daily are effective in healing erosive oesophagitis

1 reference

12 December 2020

Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a double-blind comparison with ranitidine

1 reference

12 December 2020

Ranitidine in the treatment of symptomatic gastroesophageal reflux disease

1 reference

12 December 2020

Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis

1 reference

12 December 2020

Low-dose antacids versus 400 mg cimetidine twice daily for reflux oesophagitis. A comparative, placebo-controlled, multicentre study

1 reference

12 December 2020

Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada

1 reference

12 December 2020

Treatment of reflux oesophagitis with ranitidine

1 reference

12 December 2020

The statistical basis of meta-analysis

1 reference

12 December 2020

Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The U.S. multicenter study

1 reference

12 December 2020

Cisapride in the treatment of gastro-oesophageal reflux disease

1 reference

12 December 2020

Epidemiology of reflux disease and reflux esophagitis.

1 reference

12 December 2020

Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial

1 reference

12 December 2020

Cisapride versus placebo in reflux esophagitis. A multicenter double-blind trial

1 reference

12 December 2020

Ranitidine versus cimetidine in the healing of erosive esophagitis

1 reference

12 December 2020

Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s

1 reference

12 December 2020

Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring

1 reference

12 December 2020

Prevention of relapse of reflux oesophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine

1 reference

12 December 2020

[Omeprazole (20 mg daily) compared to ranitidine (150 mg twice daily) in the treatment of esophagitis caused by reflux. Results of a double-blind randomized multicenter trial in France and Belgium]

1 reference

12 December 2020

Ranitidine and placebo in the treatment of reflux oesophagitis. A double-blind randomized trial.

1 reference

12 December 2020

Cost effectiveness as a criterion for Medicare coverage

1 reference

12 December 2020

Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group

1 reference

12 December 2020

Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study

1 reference

12 December 2020

Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study

1 reference

12 December 2020

Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. Results of a German multicenter study

1 reference

12 December 2020

Laparoscopic Nissen fundoplication is a satisfactory alternative to long-term omeprazole therapy

1 reference

12 December 2020

Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole

1 reference

12 December 2020

Reflux esophagitis therapy: sucralfate versus ranitidine in a double blind multicenter trial.

1 reference

12 December 2020

Oral cimetidine in reflux esophagitis: a double blind controlled trial

1 reference

12 December 2020

Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis

1 reference

12 December 2020

Healing and relapse of reflux esophagitis during treatment with ranitidine.

1 reference

12 December 2020

Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease

1 reference

12 December 2020

Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group

1 reference

12 December 2020

Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group

1 reference

12 December 2020

Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.

1 reference

12 December 2020

Symptomatic gastroesophageal reflux: incidence and precipitating factors

1 reference

12 December 2020

Physician ratings of appropriate indications for six medical and surgical procedures

1 reference

12 December 2020

Epidemiology of oesophageal reflux disease

1 reference

12 December 2020

Failure of sucralfate in the treatment of refractory esophagitis versus high-dose famotidine. An endoscopic study

1 reference

12 December 2020

Treatment of reflux oesophagitis. A randomized, controlled evaluation of cimetidine

1 reference

12 December 2020

Ranitidine therapy for gastroesophageal reflux disease. Results of a large double-blind trial

1 reference

12 December 2020

Ranitidine is effective therapy for erosive esophagitis.

1 reference

12 December 2020

Controlled trial of cimetidine in reflux esophagitis

1 reference

12 December 2020

Prevention of Relapse of Reflux Esophagitis after Endoscopic Healing: The Efficacy and Safety of Omeprazole Compared with Ranitidine

1 reference

12 December 2020

A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group

1 reference

12 December 2020

Australian clinical trials of omeprazole in the management of reflux oesophagitis

1 reference

12 December 2020

Cimetidine 800 mg twice daily for healing erosions and ulcers in gastroesophageal reflux disease.

1 reference

12 December 2020

Investigation of ranitidine 150 mg bd or 300 mg bd in the treatment of reflux disease

1 reference

12 December 2020

Comparing the cost-effectiveness of drug regimens in the treatment of duodenal ulcers

1 reference

12 December 2020

10.2165/00019053-199916060-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1029267346

0 references

1 reference